MX2021003131A - Antagonista de prostanoide tipo d (dp). - Google Patents
Antagonista de prostanoide tipo d (dp).Info
- Publication number
- MX2021003131A MX2021003131A MX2021003131A MX2021003131A MX2021003131A MX 2021003131 A MX2021003131 A MX 2021003131A MX 2021003131 A MX2021003131 A MX 2021003131A MX 2021003131 A MX2021003131 A MX 2021003131A MX 2021003131 A MX2021003131 A MX 2021003131A
- Authority
- MX
- Mexico
- Prior art keywords
- receptor
- useful
- acceptable salts
- nervous system
- central nervous
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D309/06—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/64—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
- C07C235/76—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
- C07C235/78—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C327/00—Thiocarboxylic acids
- C07C327/38—Amides of thiocarboxylic acids
- C07C327/48—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Auxiliary Devices For Music (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018175758 | 2018-09-20 | ||
| PCT/JP2019/036725 WO2020059790A1 (ja) | 2018-09-20 | 2019-09-19 | Ｄｐアンタゴニスト |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021003131A true MX2021003131A (es) | 2021-05-14 |
Family
ID=69888481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021003131A MX2021003131A (es) | 2018-09-20 | 2019-09-19 | Antagonista de prostanoide tipo d (dp). |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US11319296B2 (enExample) |
| EP (1) | EP3854781B1 (enExample) |
| JP (2) | JP7021709B2 (enExample) |
| KR (2) | KR20220107330A (enExample) |
| CN (1) | CN112739680A (enExample) |
| AU (1) | AU2019341082A1 (enExample) |
| BR (1) | BR112021005260A2 (enExample) |
| CA (1) | CA3113210A1 (enExample) |
| ES (1) | ES2982217T3 (enExample) |
| IL (2) | IL310383A (enExample) |
| MX (1) | MX2021003131A (enExample) |
| NZ (1) | NZ774113A (enExample) |
| PH (1) | PH12021550549A1 (enExample) |
| SG (1) | SG11202102566YA (enExample) |
| TW (2) | TWI784199B (enExample) |
| WO (1) | WO2020059790A1 (enExample) |
| ZA (1) | ZA202101887B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11319296B2 (en) * | 2018-09-20 | 2022-05-03 | Ono Pharmaceutical Co., Ltd. | DP antagonist |
| TW202146394A (zh) * | 2020-03-19 | 2021-12-16 | 日商小野藥品工業股份有限公司 | 苯乙酸化合物之結晶 |
| JP2024016311A (ja) * | 2020-12-24 | 2024-02-07 | 小野薬品工業株式会社 | Ｅｐ２アンタゴニスト |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4994479A (en) * | 1985-04-03 | 1991-02-19 | Yamanouchi Pharmaceutical Co., Ltd. | Phenylene derivatives and anti-allergic use thereof |
| JPS63159342A (ja) * | 1985-04-03 | 1988-07-02 | Yamanouchi Pharmaceut Co Ltd | 新規カルボン酸化合物 |
| MXPA04009095A (es) * | 2002-03-19 | 2004-12-06 | Ono Pharmaceutical Co | Compuesto de acido carboxilico y agente farmaceutico que comprende el compuesto como ingrediente activo. |
| AU2004274324B2 (en) * | 2003-09-17 | 2009-11-05 | Ono Pharmaceutical Co., Ltd. | Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient |
| EP1723132A1 (en) * | 2004-02-12 | 2006-11-22 | Asterand Uk Limited | Ep2 receptor agonists |
| US7803786B2 (en) | 2004-06-17 | 2010-09-28 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions and related methods of use |
| TWI410410B (zh) * | 2007-08-10 | 2013-10-01 | Ono Pharmaceutical Co | Phenylacetic acid compounds |
| CA2849350A1 (en) | 2011-09-26 | 2013-04-04 | Grunenthal Gmbh | Amine substituted methanesulfonamide derivatives as vanilloid receptor ligands |
| JP2020502189A (ja) | 2016-12-20 | 2020-01-23 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | インドールアミン２，３−ジオキシゲナーゼのモジュレーター |
| JP6533249B2 (ja) | 2017-04-21 | 2019-06-19 | 山佐株式会社 | 遊技機用基板ケースの取り付け構造及び遊技機 |
| CN110785408A (zh) | 2017-06-28 | 2020-02-11 | 葛兰素史克知识产权开发有限公司 | 吲哚胺2,3-双加氧酶的调节剂 |
| US11319296B2 (en) | 2018-09-20 | 2022-05-03 | Ono Pharmaceutical Co., Ltd. | DP antagonist |
-
2019
- 2019-09-19 US US17/276,284 patent/US11319296B2/en active Active
- 2019-09-19 BR BR112021005260-7A patent/BR112021005260A2/pt not_active Application Discontinuation
- 2019-09-19 ES ES19862361T patent/ES2982217T3/es active Active
- 2019-09-19 KR KR1020227025551A patent/KR20220107330A/ko not_active Withdrawn
- 2019-09-19 IL IL310383A patent/IL310383A/en unknown
- 2019-09-19 JP JP2020548589A patent/JP7021709B2/ja active Active
- 2019-09-19 AU AU2019341082A patent/AU2019341082A1/en not_active Abandoned
- 2019-09-19 NZ NZ774113A patent/NZ774113A/en unknown
- 2019-09-19 SG SG11202102566YA patent/SG11202102566YA/en unknown
- 2019-09-19 CA CA3113210A patent/CA3113210A1/en active Pending
- 2019-09-19 KR KR1020217008017A patent/KR102425709B1/ko active Active
- 2019-09-19 TW TW108133822A patent/TWI784199B/zh not_active IP Right Cessation
- 2019-09-19 MX MX2021003131A patent/MX2021003131A/es unknown
- 2019-09-19 WO PCT/JP2019/036725 patent/WO2020059790A1/ja not_active Ceased
- 2019-09-19 TW TW111143026A patent/TWI822457B/zh active
- 2019-09-19 EP EP19862361.3A patent/EP3854781B1/en active Active
- 2019-09-19 CN CN201980061636.8A patent/CN112739680A/zh active Pending
-
2021
- 2021-03-11 IL IL281433A patent/IL281433A/en unknown
- 2021-03-12 PH PH12021550549A patent/PH12021550549A1/en unknown
- 2021-03-19 ZA ZA2021/01887A patent/ZA202101887B/en unknown
-
2022
- 2022-01-13 JP JP2022003838A patent/JP7338711B2/ja active Active
- 2022-03-15 US US17/695,796 patent/US20220204468A1/en not_active Abandoned
-
2024
- 2024-10-14 US US18/915,276 patent/US20250042870A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR102425709B1 (ko) | 2022-07-28 |
| US20250042870A1 (en) | 2025-02-06 |
| IL281433A (en) | 2021-04-29 |
| JPWO2020059790A1 (ja) | 2021-09-02 |
| KR20220107330A (ko) | 2022-08-02 |
| EP3854781B1 (en) | 2024-05-22 |
| WO2020059790A1 (ja) | 2020-03-26 |
| TWI784199B (zh) | 2022-11-21 |
| AU2019341082A1 (en) | 2021-04-15 |
| EP3854781A1 (en) | 2021-07-28 |
| JP2022058610A (ja) | 2022-04-12 |
| TWI822457B (zh) | 2023-11-11 |
| US20220204468A1 (en) | 2022-06-30 |
| JP7338711B2 (ja) | 2023-09-05 |
| US11319296B2 (en) | 2022-05-03 |
| ZA202101887B (en) | 2022-10-26 |
| JP7021709B2 (ja) | 2022-02-17 |
| TW202308986A (zh) | 2023-03-01 |
| CA3113210A1 (en) | 2020-03-26 |
| NZ774113A (en) | 2024-09-27 |
| US20220033371A1 (en) | 2022-02-03 |
| IL310383A (en) | 2024-03-01 |
| EP3854781A4 (en) | 2022-02-23 |
| TW202023535A (zh) | 2020-07-01 |
| PH12021550549A1 (en) | 2022-02-14 |
| KR20210065944A (ko) | 2021-06-04 |
| ES2982217T3 (es) | 2024-10-15 |
| CN112739680A (zh) | 2021-04-30 |
| SG11202102566YA (en) | 2021-04-29 |
| BR112021005260A2 (pt) | 2021-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023007192A (es) | Inhibidores de prmt5. | |
| MX393395B (es) | Derivado de heteroaril[4,3-c]pirimidina-5-amina, método de preparación del mismo y usos médicos del mismo. | |
| MA38380A1 (fr) | Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr) | |
| EA202091262A1 (ru) | Пиперидиновые модуляторы рецепторов cxcr7 | |
| CR9304A (es) | Antagonistas del receptor de glucagon, preparaciones y usos terapeuticos | |
| PH12021550549A1 (en) | Dp antagonist | |
| PH12022551359A1 (en) | Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases | |
| NZ736055A (en) | Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators | |
| MY208400A (en) | Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (ror) and pharmaceutical uses thereof | |
| ZA202002762B (en) | Benzimidazole derivatives and their uses | |
| EA202191955A1 (ru) | Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы | |
| EA201891710A1 (ru) | Терапевтические соединения | |
| MA43052B1 (fr) | Inhibiteurs de la kallicréine plasmatique humaine | |
| EA036542B9 (ru) | Галоген-замещенные пиперидины в качестве модуляторов орексинового рецептора | |
| MA38679A1 (fr) | Modulateurs du récepteur de cxcr7 | |
| EA201791480A1 (ru) | Новые производные бензимидазола в качестве антигистаминных агентов | |
| MX2019006942A (es) | Agonistas de receptores de oxitocina no peptidicos. | |
| MX379373B (es) | Derivado de sulfonamida heterocíclico y medicina que contiene el mismo. | |
| CR20240353A (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa | |
| CY1123185T1 (el) | Παραγωγα ινδολιου | |
| MX2021003508A (es) | Derivados de 5-azaindazol como antagonistas del receptor de adenosina. | |
| EA201892529A1 (ru) | Комбинация чистых антагонистов 5-htрецепторов с ингибиторами ацетилхолинэстеразы | |
| GEP20257771B (en) | Compounds and compositions as sppl2a inhibitors | |
| SA521421098B1 (ar) | -h4 مركبات بيريدو بيريميدينات كمثبطات مستقبل هستامين | |
| AU2016407426A1 (en) | Triple combination of pure 5-HT6 receptor antagonists, Acetylcholinesterase inhibitors and NMDA receptor antagonist |